Theranica
Theranica is a medical device company based in Israel with offices in the United States. Theranica has developed the Nerivio® device for the treatment of migraine. Nerivio is a discrete, non-invasive electrical stimulator placed on the upper arm and controlled via a smartphone app. Clinical trials have demonstrated that the device offers efficacy comparable to, or greater than, current pharmaceutical therapies with fewer side-effects. These trials and several real-world, evidence studies, with thousands of patients, have also shown Nerivio to be able to be used as a standalone treatment or in combination with existing treatments.
Eligible for insurance coverage and available to patients seeking cost-effective drug-free therapies for migraine, Nerivio can be prescribed by any certified healthcare provider in the U.S. and is shipped to patients’ homes through several specialty pharmacies.
Nerivio is cleared for marketing in the US and Europe for the acute treatment of migraine and received positive results in preventive treatment of migraine.
Latest news from Theranica
Jan 10, 2023
Theranica Enters Into Agreement With Dr. Reddy's for Commercializing Nerivio® in India
February 28, 2023
Theranica’s Nerivio® Cleared by FDA for Preventive Treatment of Migraine
April 12, 2023
Nerivio® Proven Effective in Real-World Setting as Drug-Free Acute Treatment of Migraine for Adolescents
June 21, 2023
Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women
September 28, 2023
First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting
November 14, 2023
Theranica Enters Into Agreement With Dr. Reddy’s for Commercializing Nerivio® in Europe
February 20, 2024
Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA
July 25, 2024
New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12
November 14, 2024
FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above
December 12, 2022